Mycenax Biotech Cash Flow Conversion Efficiency
Mycenax Biotech cash flow conversion efficiency. Based on the latest financial reports, Mycenax Biotech (4726) has a cash flow conversion efficiency ratio of -0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-50.35 Million ≈ $-1.59 Million USD) by net assets (NT$1.64 Billion ≈ $51.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Mycenax Biotech (2017–2024)
Cash flow conversion efficiency of Mycenax Biotech from 2017 to 2024. This chart illustrates how Mycenax Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Mycenax Biotech stock quote for real-time trading data and today's change.
Mycenax Biotech Cash Flow Conversion Ratio Explained
Mycenax Biotech cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Mycenax Biotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mycenax Biotech ranked by their cash flow conversion efficiency. Also see 4726 market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jay Bharat Maruti Limited
NSE:JAYBARMARU
|
0.044x |
|
Al-Bad Massuot Yitzhak Ltd
TA:ALBA
|
0.065x |
|
Bera Holding AS
IS:BERA
|
0.013x |
|
National CineMedia Inc
NASDAQ:NCMI
|
-0.004x |
|
Whitehawk Therapeutics, Inc.
NASDAQ:WHWK
|
-0.098x |
|
TIZIANA LIFE SCIENCES LTD
F:0RP
|
N/A |
|
Kolmar BNH Co. Ltd
KQ:200130
|
0.049x |
|
PROQR THERAPEUTICS EO-04
F:0PQ
|
-0.271x |
Annual Cash Flow Conversion Efficiency for Mycenax Biotech (2017–2024)
The table below shows the annual cash flow conversion efficiency of Mycenax Biotech from 2017 to 2024. Review Mycenax Biotech free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$2.02 Billion ≈ $63.75 Million |
NT$-191.68 Million ≈ $-6.04 Million |
-0.095x | -76.72% |
| 2023-12-31 | NT$2.45 Billion ≈ $77.10 Million |
NT$-131.18 Million ≈ $-4.13 Million |
-0.054x | -10.84% |
| 2022-12-31 | NT$3.11 Billion ≈ $97.84 Million |
NT$-150.19 Million ≈ $-4.73 Million |
-0.048x | +36.95% |
| 2021-12-31 | NT$1.91 Billion ≈ $60.07 Million |
NT$-146.23 Million ≈ $-4.61 Million |
-0.077x | -153.36% |
| 2020-12-31 | NT$1.21 Billion ≈ $38.17 Million |
NT$174.17 Million ≈ $5.49 Million |
0.144x | +212.55% |
| 2019-12-31 | NT$1.10 Billion ≈ $34.72 Million |
NT$-140.74 Million ≈ $-4.43 Million |
-0.128x | +35.74% |
| 2018-12-31 | NT$907.01 Million ≈ $28.58 Million |
NT$-180.27 Million ≈ $-5.68 Million |
-0.199x | -399.11% |
| 2017-12-31 | NT$1.14 Billion ≈ $36.04 Million |
NT$-45.55 Million ≈ $-1.44 Million |
-0.040x | -- |
About Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more